Aduro Biotech, Inc. (NASDAQ:ADRO) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Tuesday, July 25th.
A number of other analysts have also weighed in on ADRO. Cowen and Company began coverage on shares of Aduro Biotech in a report on Tuesday, July 18th. They issued an “outperform” rating for the company. Canaccord Genuity reissued a “buy” rating and issued a $30.00 price target on shares of Aduro Biotech in a report on Wednesday, May 3rd. HC Wainwright started coverage on shares of Aduro Biotech in a report on Monday, May 1st. They issued a “buy” rating and a $18.00 price target for the company. Rodman & Renshaw started coverage on shares of Aduro Biotech in a report on Monday, May 1st. They set a “buy” rating and a $18.00 target price for the company. Finally, Zacks Investment Research raised shares of Aduro Biotech from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a report on Tuesday, July 4th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $19.00.
Shares of Aduro Biotech (NASDAQ ADRO) remained flat at $12.25 during trading on Tuesday. 388,171 shares of the company’s stock were exchanged. The firm’s 50 day moving average price is $12.14 and its 200-day moving average price is $10.93. The firm’s market cap is $902.53 million. Aduro Biotech has a 52-week low of $8.75 and a 52-week high of $16.43.
Aduro Biotech (NASDAQ:ADRO) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.02. The company had revenue of $5.90 million during the quarter, compared to analyst estimates of $3.98 million. Aduro Biotech had a negative net margin of 609.58% and a negative return on equity of 43.92%. The business’s revenue for the quarter was down 84.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.03 EPS. On average, equities research analysts predict that Aduro Biotech will post ($1.33) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This story was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://stocknewstimes.com/2017/08/07/aduro-biotech-inc-adro-upgraded-at-bidaskclub-updated.html.
In other news, COO Gregory W. Schafer sold 40,000 shares of the business’s stock in a transaction on Wednesday, June 28th. The shares were sold at an average price of $11.26, for a total value of $450,400.00. Following the completion of the transaction, the chief operating officer now owns 160,979 shares of the company’s stock, valued at approximately $1,812,623.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Thomas W. Dubensky sold 50,000 shares of the business’s stock in a transaction on Thursday, July 6th. The shares were sold at an average price of $11.33, for a total transaction of $566,500.00. Following the completion of the transaction, the insider now directly owns 51,700 shares of the company’s stock, valued at approximately $585,761. The disclosure for this sale can be found here. Insiders have sold a total of 419,205 shares of company stock valued at $4,410,591 in the last ninety days. Company insiders own 6.60% of the company’s stock.
Several institutional investors have recently made changes to their positions in the stock. Blair William & Co. IL raised its position in shares of Aduro Biotech by 0.4% in the first quarter. Blair William & Co. IL now owns 189,790 shares of the biotechnology company’s stock valued at $2,135,000 after buying an additional 735 shares during the period. Legal & General Group Plc raised its position in shares of Aduro Biotech by 11.2% in the second quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 1,043 shares during the period. American International Group Inc. raised its position in shares of Aduro Biotech by 7.1% in the first quarter. American International Group Inc. now owns 21,840 shares of the biotechnology company’s stock valued at $235,000 after buying an additional 1,447 shares during the period. Parametric Portfolio Associates LLC raised its position in shares of Aduro Biotech by 15.9% in the first quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock valued at $166,000 after buying an additional 2,119 shares during the period. Finally, Tudor Investment Corp ET AL raised its position in shares of Aduro Biotech by 34.8% in the first quarter. Tudor Investment Corp ET AL now owns 15,436 shares of the biotechnology company’s stock valued at $166,000 after buying an additional 3,984 shares during the period. 35.60% of the stock is owned by institutional investors.
Aduro Biotech Company Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
